Fastest Topical Anesthetic: 3268 (Topical or Epidermis Anesthetic)

In the United States, each year approximately 18 million venous access procedures (Requires that tubes be placed into the body which receives medications, including an IV or nutrients directly into the blood stream or gastrointestinal system or blood can be drawn) are performed in pediatric patients. During this procedure on pediatric patients, medical guidelines advocate the use of topical anesthetics. However, compliance is difficult to enforce, because of the limitation of available products.

Anesiva Incorporated (formerly Corgentech Incorporated - name changed on June 21, 2006), a late stage biopharmaceutical company develops commercialized novel of therapeutic treatments for pain. The company is based in South San Francisco, California. Currently, the company is working on developing three pain relief applications, one of which is called 3268, in the most advance stage of testing, and has completed Phase 3 clinical trials. The second drug is called 4975, undergoing mid-stage clinical trials, and third is called 1207, undergoing pre-clinical development and is anticipated to enter the clinic stage of testing in 2006. Anesiva Incorporated announced in July 2006, will be filling to seek approval from the Food and Drug Administration (FDA) for the sale and distribution of 3268, in the timeframe of September / October 2006. 3268 has shown to substantially reduce pain as a local anesthetic associated with vein punctures (Process obtaining a sample venous blood from a patient's vein). The topical anesthetic would be for pediatric patients, (Also, applicable for adults upon completing further trial study.) and the company is hopefully the FDA will approve the anesthetic for use in 2007.